Analysis of how life sciences organizations go to market, grow, and scale in regulated environments.
This section covers commercial transformation, omnichannel strategy, customer engagement, operating models, content, and the structural decisions that shape execution across pharma, MedTech, and digital health.
Europe’s first biosimilar recommended under a pathway that no longer expects a comparative efficacy trial moves the evidence burden into analytics and manufacturing. Most of the next wave is already being designed the same way.
New tozorakimab data strengthen the case for treating a broader COPD population. A credible launch forecast must separately model eligibility, identification, funded assessment and sustained treatment.
H1 2026 SYNTHESIS · 13-MINUTE READ The product did not become less important. It became less sufficient. The first half of 2026 did not make the molecule, device or algorithm less important. It made them less sufficient. Across pharma, MedTech and digital health, advantage moved towards the institutions able to connect evidence, regulation, access, data…
Digital health companies love to talk about defensible technology. European health systems are much less romantic. They care whether the product gets used, fits the workflow, generates evidence, survives procurement and justifies reimbursement after the first enthusiasm fades. In Europe, a CE mark, a DiGA listing, a PECAN decision or a positive early value signal…
The European MedTech launch model is not failing because clinicians stopped caring about innovation. It is failing because the buying system changed faster than the commercial operating model around it. When a European MedTech launch misses its number, the review usually lands on familiar explanations: pricing pressure, reimbursement delay, procurement friction, competitor response, or slower-than-expected…
AI in Commercial Operations AI-Powered Commercial Operating Models in Life Sciences: What Actually Changes Beyond the Hype Every large pharma and MedTech company now has an AI commercial programme. Very few have a new commercial operating model. That gap is the whole story. Who Should Read It? Walk into any large life sciences commercial organisation…
Europe’s healthtech market is no longer an emerging category. It is repricing, consolidating and, selectively, preparing for public markets. That is a useful correction. The companies that matter in 2026 are not simply those with the largest funding rounds or the most polished investor narrative. They are the companies proving that digital health can survive…
Everyone talks about omnichannel. Few do it well. In medtech, digital transformation isn’t optional. It’s survival. Yet for all the noise about AI-driven journeys and seamless customer experiences, even the top players are still building the plane mid-flight. So what can smaller European medtech companies learn from the current leaders? I reviewed the publicly available…
€200 million. Not a sum we see every day in European HealthTech, especially outside AI hype-cycles. Munich-based Ortivity broke the mould—raising a mega‑round led by Apheon, with new capital from Unigestion, allowing existing shareholders a partial exit. What is Ortivity? If you are not living in Germany, you probably never heard about it. Founded in 2022…
FAQ #2: How Does Omnichannel Marketing Differ from Traditional Marketing in Healthcare? The fundamental difference between omnichannel and traditional healthcare marketing lies in customer-centricity versus channel-centricity. Traditional marketing approaches often prioritize product promotion through isolated channels, while omnichannel marketing focuses on creating integrated customer journeys that provide value at every touchpoint.1 Traditional Healthcare Marketing Characteristics: Omnichannel…